Niksar tab 20mg 30 pc

$15.94

Niksar tab 20mg 30 pc

Quantity:

SKU: 1465104029 Categories: , Tags: ,

Description

Composition
Active substance:
1 tablet contains: bilastin – 20.00 mg ;.
Excipients:
Microcrystalline Cellulose – 103,00 mg, carboxy metilkrahmal sodium (Type A) – 1.00 mg colloidal silicon dioxide – 0.50 mg magnesium stearate – 0.50 mg.
Description:
Oval, biconvex tablets with a white sided risk for division.
Product form:
Tablets, 20 mg.
10 tablets in blisters (blister) [aluminum foil / aluminum foil].
1, 2, 3, 4 or 5 blisters with instructions for use in a cardboard package.
Contraindications
Hypersensitivity to bilastinu or auxiliary components of the drug; age 12 years (effectiveness and safety have been established); Pregnancy and breast-feeding.
Dosage
20 mg
Indications
– Allergic (seasonal and perennial) rhinoconjunctivitis: elimination or relief of symptoms (sneezing, feeling of nasal congestion, itching of the nasal mucosa, runny nose, burning sensation and itching in the eyes, redness of eyes, watery eyes). – Urticaria: the elimination or reduction of pruritus, rash.
Interaction with other drugs
With simultaneous application bilastina with ketoconazole or erythromycin area under the curve “concentration-time» (AUC) bilastina increased by 2 times, and the maximum concentration (Cmah) – 2-3.
With simultaneous application bilastina 20 mg and diltiazem 60mg bilastina Cmax increased by 50%. Similar effects can be explained by the interaction at the level of the carrier proteins (including, P-glycoprotein), responsible for the elimination of drugs from the intestine cells, which is a substrate bilastin.
With simultaneous application bilastina and other drugs that are substrates or inhibitors of P-glycoprotein (e.g., cyclosporin) can increase bilastina plasma concentration.
Grapefruit and other fruit juices bilastina reduced bioavailability by 30%. This interaction is due to the ability to inhibit the activity of protein fruit-organic anion transporter OATP1A2, for which a substrate bilastin. Drugs that are substrates or OATP1A2 inhibitors (e.g., ritonavir or rifampicin) bilastina can reduce the concentration in the blood plasma.
Bilastin does not increase the effect of ethanol on the central nervous system.
With simultaneous application bilastina and lorazepam lorazepam gain suppressing effect on the central nervous system have been identified.
Overdose
Symptoms: bilastina when applied in a dose exceeding the recommended 10-11 times, side effects occurred 2 times more often than with placebo. Most often observed the following symptoms: dizziness, headache, nausea. Serious side effects, including, a significant lengthening of the interval QT, were noted.
Treatment: symptomatic and supportive therapy. No specific antidote.
pharmachologic effect
Pharmacological group:
Antiallergic agent – H1-histamine receptor blocker.
Pharmacodynamics:
Bilastin – long acting antihistamine selectively blocks peripheral H1-receptors.
A significant therapeutic effect was observed one hour after administration of the drug, antihistaminic activity lasts for 24 h.
Perhaps a slight penetration of the blood brain barrier bilastina, but bilastin no significant effects on the central nervous system and does not cause sedation.
No anticholinergic action. QT prolongation on the ECG is not observed.
Pharmacokinetics:
Suction. After ingestion bilastin is rapidly absorbed from the gastrointestinal tract. The time to reach maximum plasma concentration (TSmah) is 1.3 hours. Bilastina bioavailability when administered is 61%. Simultaneous eating reduces the bioavailability bilastina 30%. Accumulation of the drug is observed. Communication with plasma proteins – 84-90%.
Metabolism and excretion. Bilastin significantly metabolized after single use bilastina to 95% of the dose is excreted unchanged by the kidneys (28.3%) and in bile (66.5%). The half-life (T1 / 2) is an average of 14.5 hours.
In renal failure of moderate severity (glomerular filtration rate (GFR) was 30-50 ml / min / 1.73 m2) to severe (GFR
When liver failure clinically significant changes in pharmacokinetic parameters bilastina occurs because bilastin significantly metabolized in the liver.
Bilastina pharmacokinetic parameters in elderly patients are similar to those in younger patients.
Pregnancy and breast-feeding
Use of the drug Niksar® contraindicated during pregnancy due to lack of clinical data on the use of safety in pregnant women.
In the absence of data on the penetration bilastina into breast milk, if necessary, the use of Niksar® drug during breastfeeding at the time of admission are advised to stop breastfeeding.
Conditions of supply of pharmacies
On prescription.
side effects
Possible side effects are listed below in descending frequency of occurrence of cases: very often (> 1/10), often (> 1/100
special instructions
In patients with renal insufficiency moderate severity (GFR 30-50 ml / min / 1.73 m2) to severe (GFR
The effect on the ability to operate vehicles, machinery
In a study conducted to evaluate the effect bilastina 20 mg on the ability to drive vehicles, the negative effect of the drug was not detected. However, patients should be warned that in rare cases may cause dizziness, drowsiness, which in turn may affect the ability to drive vehicles or to carry out other activities that require full attention. When the described adverse events should refrain from carrying out these activities.
Storage conditions
At a temperature of not higher than 30 C.
Drug store out of reach of children !.
Dosing and Administration
Inside.
If your doctor prescribed otherwise, for the relief of symptoms of allergic rhinoconjunctivitis and urticaria recommended dose Niksar® following product:
Adults and children over 12 years: 1 tablet Niksar® preparation corresponding to 20 mg bilastina, once a day.
The maximum daily dose of 20 mg bilastina, as increasing the dose does not lead to increased therapeutic effect.
Tablet is taken one hour before eating or 2 hours after a meal (or fruit juice).
In allergic rhinoconjunctivitis drug is used during the whole period of contact with allergens.
Hives treatment should be continued until the disappearance or relief of symptoms.
In patients with impaired liver function and kidney dose adjustment is required.
Elderly patients No dose adjustment is required. Experience of using Niksar® drug in people over 65 years is negligible.
Information
Appearance may differ from that depicted in the picture. There are contraindications. You need to read the manual or consult with a specialist

Additional information

Weight0.100 kg
Manufacturer

Berlin Chemie

There are no reviews yet.

Add your review